#BEGIN_DRUGCARD DB01764

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Converted to an active non-conjugated metabolite by hydrolysis.

# Brand_Mixtures:
Synercid (Dalfopristin + Quinupristin)

# Brand_Names:
Not Available

# CAS_Registry_Number:
112362-50-2

# ChEBI_ID:
Not Available

# Chemical_Formula:
C34H50N4O9S

# Chemical_IUPAC_Name:
(6R,10R,11R,21S)-6-{[2-(diethylamino)ethane]sulfonyl}-21-hydroxy-11,19-dimethyl-10-(propan-2-yl)-9,26-dioxa-3,15,28-triazatricyclo[23.2.1.0^{3,7}]octacosa-1(27),12,17,19,25(28)-pentaene-2,8,14,23-tetrone

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
2241323

# Description:
Dalfopristin is a combination of two antibiotics (Dalfopristin and quinupristin) used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium. It is not effective against Enterococcus faecalis infections. Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.

# Dosage_Forms:
Solution	Intravenous

# Drug_Category:
Anti-Bacterial Agents
Antibacterial Agents

# Drug_Interactions:
Not Available

# Drug_Reference:
10651391	Lamb HM, Figgitt DP, Faulds D: Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections. Drugs. 1999 Dec;58(6):1061-97.
11190346	Paradisi F, Corti G, Messeri D: Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am. 2001 Jan;85(1):1-17.
11219478	Allington DR, Rivey MP: Quinupristin/dalfopristin: a therapeutic review. Clin Ther. 2001 Jan;23(1):24-44.
11764864	Manzella JP: Quinupristin-dalfopristin: a new antibiotic for severe gram-positive infections. Am Fam Physician. 2001 Dec 1;64(11):1863-6.

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Dalfopristin

# HET_ID:
DOL

# Half_Life:
The elimination half-life is approximately 0.70 hours.

# InChI_Identifier:
InChI=1S/C34H50N4O9S/c1-7-37(8-2)16-17-48(44,45)28-13-15-38-31(28)34(43)47-32(22(3)4)24(6)11-12-29(41)35-14-9-10-23(5)18-25(39)19-26(40)20-30-36-27(21-46-30)33(38)42/h9-12,18,21-22,24-25,28,31-32,39H,7-8,13-17,19-20H2,1-6H3,(H,35,41)/b10-9-,12-11-,23-18-/t24-,25-,28-,31?,32-/m1/s1

# InChI_Key:
InChIKey=SUYRLXYYZQTJHF-FUODUHIRSA-N

# Indication:
For the treatment of bacterial infections (usually in combination with quinupristin).

# KEGG_Compound_ID:
C08033

# KEGG_Drug_ID:
D00853

# LIMS_Drug_ID:
1764

# Mechanism_Of_Action:
The site of action of dalfopristin is the bacterial ribosome. Dalfopristin 
has been shown to inhibit the early phase of protein synthesis.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
690.847

# Molecular_Weight_Mono:
690.329849908

# Organisms_Affected:
Enteric bacteria and other eubacteria

# PDB_Experimental_ID:
1MRL

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164746234

# Pharmacology:
Dalfopristin is a streptogramin antibiotic, derived from pristinamycin IIA.

# Predicted_LogP_Hydrophobicity:
2.57

# Predicted_LogS:
-4

# Predicted_Water_Solubility:
7.16e-02 g/l

# Primary_Accession_No:
DB01764

# Protein_Binding:
Moderate

# PubChem_Compound_ID:
21943991

# PubChem_Substance_ID:
46506561

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
EXPT01246

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
CCN(CC)CCS(=O)(=O)[C@]1([H])CCN2C(=O)C3=COC(=N3)CC(=O)C[C@H](O)\C=C(\C)/C=C\CNC(=O)\C=C/[C@@H](C)[C@@H](C(C)C)OC(=O)C12

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Dalfopristina [inn-spanish]
Dalfopristine [inn-french]
Dalfopristinum [inn-latin]

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:20:28 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Dalfopristin

# pKa_Isoelectric_Point:
Not Available

# Phase_1_Metabolizing_Enzyme_1_Gene_Name:
CYP3A4

# Phase_1_Metabolizing_Enzyme_1_ID:
4512

# Phase_1_Metabolizing_Enzyme_1_Name:
Cytochrome P450 3A4

# Phase_1_Metabolizing_Enzyme_1_Protein_Sequence:
>Cytochrome P450 3A4
MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMF
DMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISI
AEDEEWKRLRSLLSPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYS
MDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICV
FPREVTNFLRKSVKRMKESRLEDTQKHRVDFLQLMIDSQNSKETESHKALSDLELVAQSI
IFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVV
NETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDPKYWTEPEKFLPERFS
KKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLG
GLLQPEKPVVLKVESRDGTVSGA

# Phase_1_Metabolizing_Enzyme_1_SwissProt_ID:
P08684

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
20428664	Manfredi R, Sabbatani S: Novel pharmaceutical molecules against emerging resistant gram-positive cocci. Braz J Infect Dis. 2010 Jan-Feb;14(1):96-108.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L12033

# Drug_Target_1_GenBank_ID_Protein:
433715

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
vatD

# Drug_Target_1_Gene_Sequence:
>630 bp
ATGGGTCCGAATCCTATGAAAATGTATCCTATAGAAGGAAACAAATCAGTACAATTTATC
AAACCTATTTTAGAAAAATTAGAAAATGTTGAGGTTGGAGAATACTCATATTATGATTCT
AAGAATGGAGAAACTTTTGATAAGCAAATTTTATATCATTATCCAATCTTAAACGATAAG
TTAAAAATAGGTAAATTTTGCTCAATAGGACCAGGTGTAACTATTATTATGAATGGAGCA
AATCATAGAATGGATGGCTCAACATATCCATTTAATTTATTTGGTAATGGATGGGAGAAA
CATATGCCAAAATTAGATCAACTACCTATTAAGGGGGATACAATAATAGGTAATGATGTA
TGGATAGGAAAAGATGTTGTAATTATGCCAGGAGTAAAAATCGGGGATGGTGCAATAGTA
GCTGCTAATTCTGTTGTTGTAAAAGATATAGCGCCATACATGTTAGCTGGAGGAAATCCT
GCTAACGAAATAAAACAAAGATTTGATCAAGATACAATAAATCAGCTGCTTGATATAAAA
TGGTGGAATTGGCCAATAGACATTATTAATGAGAATATAGATAAAATTCTTGATAATAGC
ATCATTAGAGAAGTCATATGGAAAAAATGA

# Drug_Target_1_General_Function:
Involved in acyltransferase activity

# Drug_Target_1_General_References:
8257133	Rende-Fournier R, Leclercq R, Galimand M, Duval J, Courvalin P: Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145. Antimicrob Agents Chemother. 1993 Oct;37(10):2119-25.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
2285

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
23650

# Drug_Target_1_Name:
Streptogramin A acetyltransferase

# Drug_Target_1_Number_of_Residues:
209

# Drug_Target_1_PDB_ID:
1MR7

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00132	Hexapep

# Drug_Target_1_Protein_Sequence:
>Streptogramin A acetyltransferase
MGPNPMKMYPIEGNKSVQFIKPILEKLENVEVGEYSYYDSKNGETFDKQILYHYPILNDK
LKIGKFCSIGPGVTIIMNGANHRMDGSTYPFNLFGNGWEKHMPKLDQLPIKGDTIIGNDV
WIGKDVVIMPGVKIGDGAIVAANSVVVKDIAPYMLAGGNPANEIKQRFDQDTINQLLDIK
WWNWPIDIINENIDKILDNSIIREVIWKK

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
Inactivates the A compounds of streptogramin antibiotics by acetylation, thus providing resistance to these antibiotics

# Drug_Target_1_SwissProt_ID:
P50870

# Drug_Target_1_SwissProt_Name:
VATD_ENTFC

# Drug_Target_1_Synonyms:
EC 2.3.1.-
Vat(D)
Virginiamycin acetyltransferase D

# Drug_Target_1_Theoretical_pI:
5.75

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB01764
